Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
复制标题
DOI：
10.3109/10428194.2013.815349
复制
发表时间：
2014-04-01
影响因子：
2.6
通讯作者：
Trneny, Marek
中科院分区：
文献类型：
--
作者：
Salek, David;Vesela, Pavla;Trneny, Marek
尽管已经建立了套细胞淋巴瘤（MCL）患者的预后模型（MIPI，套细胞淋巴瘤国际预后指数），但其在利妥昔单抗时代的日常实践中的临床意义仍存在争议。分析了来自捷克淋巴瘤项目数据库的235例MCL患者的数据。评估所有患者和155例利妥昔单抗治疗（RT）患者亚组的MIPI、简化MIPI（s-MIPI）和Ki-67增殖指数。MIPI将所有患者分为低风险（22%），中等风险（29%）和高风险（49%）亚组，中位总生存期分别为105.8 vs. 54.1 vs. 24.6个月（p < 0.001）。s-MIPI显示了类似的结果。这两个指标的有效性在RT患者中得到证实。我们证实Ki-67指数是所有患者和RT亚组总生存期的一个强有力的单一预后因素（64.4 vs. 20.1个月，p < 0.001）。我们的研究结果证实了MIPI、s-MIPI和Ki-67在利妥昔单抗时代对MCL风险分层的临床相关性。
Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.